Pyxis Oncology, Inc.
NASDAQ:PYXSBiotechnology
+$0.11 today
- Market cap
- $168.65M
- Beta
- 1.43
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.29
Volume 0.75M
Average 0.50M
PYXS Operating Cash Flow
Cash generated by the company's core business operations during the period.
Pyxis Oncology, Inc.NASDAQ: PYXS
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $26M (cash outflow) rose 15.4% year over year, ahead of the +12.6% change in trailing-twelve-month operating cash flow. Sequentially, it rose 149.4% from the prior quarter. Over 3 fiscal years it compounded at -10.8% a year.
Context
- Operating cash flow amounted to 458.2% of revenue in FY2025, up 101.0 pp from a year earlier.
- Operating cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +15.4% holds above the trailing-twelve-month pace of +12.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (63.5M) USD
- Year-over-year change
- -10.1%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (63.5M) | -10.1% |
| FY2024 | 2024-12-31 | (57.67M) | +18.4% |
| FY2023 | 2023-12-31 | (70.71M) | +20.8% |
| FY2022 | 2022-12-31 | (89.34M) | -152.9% |
| FY2021 | 2021-12-31 | (35.33M) | — |
Operating Cash Flow vs competitors
How PYXS compares with its peers on the latest reported figures
- PYXS's LTM Mar 2026 operating cash flow of $66.97M is the 7th largest of the 10 companies compared; the peer median is $87.4M.
- Its year-over-year change of +12.6% is the 4th highest of 10, against a peer median of -7.3%.
- Operating cash flow amounts to 483.2% of revenue for PYXS, versus a peer median of 627.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $147.86M | +17.2% | +3.0% | — | |
| LTM Mar 2026 | $127.99M | +14.3% | +119.6% | 350.7% | |
| LTM Mar 2026 | $101.54M | +2.2% | +13.9% | 5037.0% | |
| LTM Mar 2026 | $101.25M | -26.5% | +6.9% | 903.8% | |
| LTM Mar 2026 | $87.4M | -8.0% | — | 309.7% | |
ZURAZura Bio Limited | LTM Mar 2026 | $72.68M | +112.8% | +277.8% | — |
| LTM Mar 2026 | $66.97M | +12.6% | -10.8% | 483.2% | |
| LTM Mar 2026 | $64.39M | -24.2% | -13.2% | 28616.0% | |
| LTM Mar 2026 | $49.7M | -7.3% | +0.9% | — | |
| LTM Mar 2026 | $7.84M | -85.9% | -39.0% | 11.3% | |
| Peer median (excluding PYXS) | $87.4M | -7.3% | +4.9% | 627.3% | |
Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (75.98M) | (120.72M) | (73.79M) | (77.33M) | (79.62M) |
| Depreciation & Amortization | 647K | 709K | 1.93M | 2.98M | 4.51M |
| Deferred Income Tax | 6.28M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.44M | 15.76M | 16.95M | 12.95M | 11.8M |
| Change in Working Capital | 6.68M | 4.5M | (11.66M) | (11.82M) | 1.94M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 4.64M | (8.33M) | (3.51M) | 1.2M | 6.03M |
| Other Working Capital | 2.03M | 12.83M | (8.16M) | (13.02M) | (4.08M) |
| Other Non-Cash Items | 20.6M | 10.41M | (4.13M) | 15.56M | (2.14M) |
| Operating Cash Flow | (35.33M) | (89.34M) | (70.71M) | (57.67M) | (63.5M) |
| Capital Expenditures | (540K) | (6.4M) | (6.73M) | (237K) | (9K) |
| Acquisitions (Net) | (50K) | 0 | 6.66M | 0 | 0 |
| Purchases of Investments | (50K) | 0 | (196.83M) | (160.12M) | (107.01M) |
| Sales of Investments | 50.05K | 0 | 92.05M | 168.51M | 165.87M |
| Other Investing Activities | (50) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (590K) | (6.4M) | (104.85M) | 8.16M | 58.86M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 152.3M | 0 | 6.12M | 59.05M | 742K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 167K | 183K | (193K) | 280K | (148K) |
| Financing Cash Flow | 304.04M | 183K | 5.93M | 59.33M | 594K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 268.13M | (95.55M) | (169.63M) | 9.81M | (4.05M) |
| Free Cash Flow | (35.87M) | (95.73M) | (77.44M) | (57.91M) | (63.51M) |
Pyxis Oncology, Inc.
NASDAQ:PYXS
Intrinsic Alpha fair value
Locked
Current Price
$1.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.